C02CA04 doxazosin

CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING Alpha-adrenoreceptor antagonists

健保收載品項 TFDA 在效許可證 22 FDA 已核准

台灣藥品與外觀

台灣食藥署在效西藥許可證 22 張;以下列出 21 個品項(14 項有外觀照)。

健保收載品名:"五洲" 替你舒壓多莎錠2公絲"、"信東" 道福寧錠2毫克、"十全"落壓錠4毫克、"生達"多沙賓持續性藥效錠4毫克、〝十全〞落壓錠2毫克、〝生達〞多沙賓錠2公絲、健列舒錠2毫克、健諾心錠2公絲(甲磺酸多薩坐辛)、健諾心錠4公絲(甲磺酸多薩坐辛)、列優平持續性藥效錠4毫克、可迅持續性藥效錠4毫克、可迅錠1公絲(甲磺酸多薩坐辛)、可迅錠1毫克、可迅錠2公絲(甲磺酸多薩坐辛)、可迅錠2毫克、可迅錠4公絲

可迅錠2毫克 外觀
可迅錠2毫克
橢圓形 · 白 · 刻痕:直線 · 標記:VLE / CN 2 · 9 mm
可迅持續性藥效錠4毫克 外觀
可迅持續性藥效錠4毫克
圓形 · 白 · 刻痕:無 · 標記:CXL 4 · 9 mm
無外觀照
甲磺酸多薩坐辛
無外觀照
甲磺酸多薩坐辛
無外觀照
甲磺酸多薩唑辛
無外觀照
甲磺酸多薩唑辛
無外觀照
多薩唑辛甲磺酸鹽
健諾心錠2公絲(甲磺酸多薩坐辛) 外觀
健諾心錠2公絲(甲磺酸多薩坐辛)
圓形 · 白 · 刻痕:直線 · 標記:GBL 2 · 8.0 mm
健諾心錠4公絲(甲磺酸多薩坐辛) 外觀
健諾心錠4公絲(甲磺酸多薩坐辛)
圓形 · 白 · 刻痕:直線 · 標記:GBL 4 / 無 · 9.0 mm
無外觀照
〝十全〞落壓錠2毫克
無外觀照
心血平錠2毫克
〝生達〞多沙賓錠2公絲 外觀
〝生達〞多沙賓錠2公絲
橢圓形 · 白;;;白 · 刻痕:直線 · 標記:STD / TD 21 · 9.1 mm
"信東" 道福寧錠2毫克 外觀
"信東" 道福寧錠2毫克
橢圓形 · 白 · 刻痕:直線 · 標記:ST 2 · 9 mm
立安錠2毫克 外觀
立安錠2毫克
四邊形 · 白 · 刻痕:直線 · 標記:DOXTER 2 · 9.8 mm
薩多心錠2公絲 外觀
薩多心錠2公絲
四邊形 · 白 · 刻痕:直線 · 標記:CCP / C 67 · 9.4 mm
薩多心持續性藥效錠 4 毫克 外觀
薩多心持續性藥效錠 4 毫克
圓形 · 白 · 刻痕:無 · 9.0 mm
"生達"多沙賓持續性藥效錠4毫克 外觀
"生達"多沙賓持續性藥效錠4毫克
圓形 · 白;;;白 · 刻痕:無 · 標記:STD 738 · 8.7 mm
漢薩心持續性藥效錠4毫克 外觀
漢薩心持續性藥效錠4毫克
圓形 · 白 · 刻痕:無 · 標記:S / 4 · 8.8 mm
健列舒錠2毫克 外觀
健列舒錠2毫克
四邊形 · 白 · 刻痕:直線 · 標記:SW 2 · 9 mm
列優平持續性藥效錠4毫克 外觀
列優平持續性藥效錠4毫克
圓形 · 白 · 刻痕:無 · 10 mm
富必欣持續性藥效錠4毫克 外觀
富必欣持續性藥效錠4毫克
圓形 · 白 · 刻痕:無 · 9 mm

資料來源:食藥署「西藥許可證」+「藥品 ATC 碼」+「藥品外觀」+「藥品仿單或外盒」開放資料。外觀照與仿單連結指向食藥署原始檔。

適應症

台灣 TFDA 核准適應症

  1. 高血壓症、良性前列腺肥大。
  2. 高血壓、良性前列腺肥大。
  3. 血管擴張劑。

美國 FDA 適應症(英文原文對照)

美國 FDA 核准成分 doxazosin mesylate (商品名 Doxazosin) · 仿單更新 2024-05-15

1 INDICATIONS AND USAGE Doxazosin tablets are an alpha 1 adrenergic antagonist indicated for: ( 1 ) Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Doxazosin tablets may be used alone or in combination with other antihypertensives.

資料來源:食藥署西藥許可證適應症(中文)、openFDA US SPL(英文,僅供對照)。

健保給付規定

查無健保特殊給付規定條款;本藥品依一般健保藥品支付規定給付。

實證補充

本藥品尚無實證補充整理(未來新增 Review/指引知識時補列)。


台灣藥品與適應症:食藥署西藥許可證+ATC+外觀+仿單開放資料 · FDA:openFDA US SPL · 健保給付:健保署「全民健康保險藥品給付規定」(更新日 2026-06-09)· 實證補充:人工彙整。 本頁為資訊整理,實際給付與適應症以主管機關公告為準。